Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview

Acurx Pharmaceuticals

12/08/2026 13:45

Acurx Pharmaceuticals Inc ACXP.OQ ACXP.O is expected to  show no change in quarterly revenue when it reports  results on August 14 for the period ending June 30 2026

​LSEG's mean analyst estimate for Acurx Pharmaceuticals Inc is for a loss of 38 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Acurx Pharmaceuticals Inc is $10.00, about 580.3% above its last closing price of $1.47
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.64
-0.63
-0.62
Beat
2.4
Dec. 31 2026
-0.99
-0.99
-0.31
Beat
68.8
Sep. 30 2025
-1.44
-1.31
-1.23
Beat
6.1​
Jun. 30 2025
-2.25
-2.27
-1.89
Beat
16.6
​​Mar. 31 2025
-3.15
-3.00
-2.20
Beat
26.7
Dec. 31 2024
-3.60
-3.20
Beat
11.1​
Sep. 30 2024
-4.60
-4.00
-3.40
Beat
15
Jun. 30 2024
-4.32
-4.40
-5.20
Missed
-18.2
This summary was machine generated August 12 at 12:45 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)